Kymera Reports Early-Stage Success for Drug Meant to Rival Sanofi and Regeneron’s Dupixent

Kymera reports early-stage success for drug meant to rival Sanofi and Regeneron’s Dupixent

A new study finds preliminary signs the therapy might tamp down a class of immune signals linked with chronic conditions.

Kymera’s STAT6 Degrader for Inflammatory Disease Shows Early Success in Phase I

Kymera Therapeutics has announced positive results in an early-stage Phase I trial for an investigational drug designed to treat millions of patients experiencing symptoms of chronic inflammation and allergic reactions. This spectrum of targeted conditions, known as Th2 diseases, is characterized by dysregulation of T helper type 2 (Th2) cells in immune response and includes common conditions, such as asthma and atopic dermatitis (AD) or eczema.…

Kymera unveils ‘exceptional’ Phase 1 data for its Dupixent-in-a-pill program

The small biotech Kymera Therapeutics believes it could have a potential oral competitor to the megablockbuster Dupixent. There’s a long road ahead for Kymera’s immunology drug candidate, a protein degrader targeting STAT6 called KT-621. But ...